Skip to content

The Effectiveness of an Online Integrated Modality for Smoking Cessation Interventions in Patients with Chronic Cardiopulmonary Diseases

Construction and evaluation of an online integrated modality for smoking cessation service in a general hospital

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065044
Enrollment
Unknown
Registered
2022-10-26
Start date
2022-10-30
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco dependence

Interventions

quitline-based group:Proactive quitline interventions for smoking cessation
mHealth-based group:Integrated mHealth-based interventions for smoking cessation

Sponsors

Beijing Chao-Yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65; 2. Being diagnosed or suspected with chronic respiratory diseases (including COPD, asthma, pulmonary interstitial disease, bronchiectasis, etc.) or cardiovascular diseases (including coronary heart disease and hypertension, etc.); 3. Regular smoking >= 1 year, smoking >= 5 cigarettes per day, and smoking at the time of enrollment screening; 4. Planing to quit smoking within one month, and willing to get smoking cessation assist based on mHealth or quitline; 5. Having a smartphone and a WeChat account, being able to use WeChat skillfully.

Exclusion criteria

Exclusion criteria: 1. Difficult to understand the contents of the questionnaire; 2. Being in acute exacerbation of chronic cardiopulmonary disease or requiring hospitalization; 3. Received coronary angiography or surgical treatment in the last month or planing to receive coronary angiography or surgical treatment in the next month (including but not limited to PCI, etc.); 4. Using smoking cessation medications or other aids, including nicotine replacement therapy, bupropion, varenicline, e-cigarettes and other mHealth-based tools, such as web, WeChat Official Account, Apps, etc.; 5. Being participating in other studies on smoking cessation interventions.

Design outcomes

Primary

MeasureTime frame
Biologically validated 7-day point prevalence abstinence at 1-month follow-up;

Secondary

MeasureTime frame
Self-reported 7-day point prevalence abstinence at 3-months follow-up;Self-reported 7-day point prevalence abstinence at 6-months follow-up;Self-reported 7-day point prevalence abstinence at 12-months follow-up;Self-reported prolonged abstinence rate from 1-12 month;Quit attempt rates at 1 month/3months/6 months/12 months follow-ups;

Countries

China

Contacts

Public ContactLiang Lirong

Beijing Chao-Yang Hospital, Capital Medical University

llrcruie@163.com01085231610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026